Coherus Logo - R@2x.png
Coherus Prices Public Offering of Common Stock
16. Mai 2023 06:50 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its...
Coherus Logo - R@2x.png
Coherus Announces Proposed Public Offering of Common Stock
15. Mai 2023 16:01 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of...
Coherus Logo - R@2x.png
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
08. Mai 2023 16:05 ET | Coherus BioSciences, Inc.
– UDENYCA® autoinjector approved and ready for May 2023 launch –– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –– FDA inspection of...
Coherus Logo - R@2x.png
Coherus BioSciences to Present at Upcoming Investor Conferences in May
04. Mai 2023 16:30 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor...
Coherus Logo - R@2x.png
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
01. Mai 2023 16:07 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market...
Coherus Logo - R@2x.png
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
27. April 2023 08:05 ET | Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Coherus Logo - R@2x.png
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
06. März 2023 16:01 ET | Coherus BioSciences, Inc.
– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 –– FDA is planning the toripalimab manufacturing site inspection in Q2 2023 –– UDENYCA® autoinjector...
Coherus Logo - R@2x.png
FDA Approves UDENYCA® Autoinjector
06. März 2023 08:00 ET | Coherus BioSciences, Inc.
- UDENYCA® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing...
Coherus Logo - R@2x.png
Coherus BioSciences to Present at Upcoming Investor Conferences in March
01. März 2023 08:25 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences...
Coherus Logo - R@2x.png
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
28. Februar 2023 08:25 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be...